GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 45 filers reported holding GRITSTONE ONCOLOGY INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,068,000 | – | 75,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $9,152,000 | 15.60% |
| Frazier Life Sciences Management, L.P. | 5,237,348 | $13,460,000 | 1.04% |
| Redmile Group, LLC | 6,952,760 | $17,869,000 | 0.69% |
| Palo Alto Investors LP | 2,330,504 | $5,989,000 | 0.47% |
| ACT CAPITAL MANAGEMENT, LLC | 47,500 | $122,000 | 0.17% |
| SkyOak Wealth, LLC | 132,851 | $341,000 | 0.12% |
| Artal Group S.A. | 750,000 | $1,928,000 | 0.08% |
| CORNERCAP INVESTMENT COUNSEL INC | 77,046 | $198,000 | 0.04% |
| CAXTON ASSOCIATES LP | 95,190 | $245,000 | 0.03% |
| XTX Topco Ltd | 50,517 | $130,000 | 0.03% |